Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Orange, CA
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Aurora, CO
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Boca Raton, FL
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Boynton Beach, FL
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Brooksville, FL
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Brooksville, FL
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Hollywood, FL
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Hollywood, FL
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
New Port Richey, FL
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
New Port Richey, FL
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Augusta, GA
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Savannah, GA
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Savannah, GA
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Chicago, IL
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Skokie, IL
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Skokie, IL
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Waterloo, IA
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Waterloo, IA
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Lenexa, KA
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Lenexa, KA
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Lafayette, LA
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Lafayette, LA
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Scarborough, ME
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Scarborough, ME
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Baltimore, MD
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Prince Frederick, MD
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Prince Frederick, MD
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Lansing, MI
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Minneapolis, MN
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Reno, NV
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Reno, NV
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Rochester, NY
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Durham, NC
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Wilmington, NC
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Wilmington, NC
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Florence, SC
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Florence, SC
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Corpus Christi, TX
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Richardson, TX
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Richardson, TX
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Milwaukee, WI
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Racine, WI
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Racine, WI
Click here to add this to my saved trials
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
Probiotic Enteric Regimen For Easing Complications of Transplant : A Pilot Study (PERFECT Trial)
Status: Enrolling
Updated:  2/2/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
Probiotic Enteric Regimen For Easing Complications of Transplant : A Pilot Study (PERFECT Trial)
Status: Enrolling
Updated: 2/2/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Promoting Adherence to Lymphedema Self-care
Promoting Adherence to Lymphedema Self-care in Breast Cancer Survivors
Status: Enrolling
Updated:  2/6/2017
Vanderbilt Univeristy School Of Nursing
mi
from
Nashville, TN
Promoting Adherence to Lymphedema Self-care
Promoting Adherence to Lymphedema Self-care in Breast Cancer Survivors
Status: Enrolling
Updated: 2/6/2017
Vanderbilt Univeristy School Of Nursing
mi
from
Nashville, TN
Click here to add this to my saved trials
SentiMag® Intraoperative Comparison in Breast Cancer
A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure
Status: Enrolling
Updated:  2/6/2017
University of California San Diego, Moores Cancer Center
mi
from
La Jolla, CA
SentiMag® Intraoperative Comparison in Breast Cancer
A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure
Status: Enrolling
Updated: 2/6/2017
University of California San Diego, Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
SentiMag® Intraoperative Comparison in Breast Cancer
A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure
Status: Enrolling
Updated:  2/6/2017
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
SentiMag® Intraoperative Comparison in Breast Cancer
A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure
Status: Enrolling
Updated: 2/6/2017
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
SentiMag® Intraoperative Comparison in Breast Cancer
A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure
Status: Enrolling
Updated:  2/6/2017
UCSF Carol Franc Buck Breast Care Center
mi
from
San Francisco, CA
SentiMag® Intraoperative Comparison in Breast Cancer
A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure
Status: Enrolling
Updated: 2/6/2017
UCSF Carol Franc Buck Breast Care Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
SentiMag® Intraoperative Comparison in Breast Cancer
A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure
Status: Enrolling
Updated:  2/6/2017
Coordinated Health Breast Care Specialists
mi
from
Allentown, PA
SentiMag® Intraoperative Comparison in Breast Cancer
A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure
Status: Enrolling
Updated: 2/6/2017
Coordinated Health Breast Care Specialists
mi
from
Allentown, PA
Click here to add this to my saved trials
SentiMag® Intraoperative Comparison in Breast Cancer
A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure
Status: Enrolling
Updated:  2/6/2017
Dallas Surgical Group
mi
from
Dallas, TX
SentiMag® Intraoperative Comparison in Breast Cancer
A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure
Status: Enrolling
Updated: 2/6/2017
Dallas Surgical Group
mi
from
Dallas, TX
Click here to add this to my saved trials
SentiMag® Intraoperative Comparison in Breast Cancer
A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure
Status: Enrolling
Updated:  2/6/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
SentiMag® Intraoperative Comparison in Breast Cancer
A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure
Status: Enrolling
Updated: 2/6/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
Status: Enrolling
Updated:  2/6/2017
Marquette General Hospital
mi
from
Marquette, MI
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
Status: Enrolling
Updated: 2/6/2017
Marquette General Hospital
mi
from
Marquette, MI
Click here to add this to my saved trials
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
Status: Enrolling
Updated:  2/6/2017
DLP Maria Parham Medical Center
mi
from
Henderson, NC
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
Status: Enrolling
Updated: 2/6/2017
DLP Maria Parham Medical Center
mi
from
Henderson, NC
Click here to add this to my saved trials
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
Status: Enrolling
Updated:  2/6/2017
Lexington Medical Center
mi
from
West Columbia, SC
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
Status: Enrolling
Updated: 2/6/2017
Lexington Medical Center
mi
from
West Columbia, SC
Click here to add this to my saved trials
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
Status: Enrolling
Updated:  2/6/2017
Augusta Health
mi
from
Fishersville, VA
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program
Status: Enrolling
Updated: 2/6/2017
Augusta Health
mi
from
Fishersville, VA
Click here to add this to my saved trials
EPO906 Therapy in Patients With Advanced Breast Cancer
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/7/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
EPO906 Therapy in Patients With Advanced Breast Cancer
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/7/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
EPO906 Therapy in Patients With Advanced Breast Cancer
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/7/2017
Cancer Institute of New Jersey (CINJ)
mi
from
New Brunswick, NJ
EPO906 Therapy in Patients With Advanced Breast Cancer
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/7/2017
Cancer Institute of New Jersey (CINJ)
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
University of California at Los Angeles JonssonComprehensiveCancerCtr
mi
from
Los Angeles, CA
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
University of California at Los Angeles JonssonComprehensiveCancerCtr
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Yale University School of Medicine YaleCancerCtr-ClinTrialsOffice
mi
from
New Haven, CT
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Yale University School of Medicine YaleCancerCtr-ClinTrialsOffice
mi
from
New Haven, CT
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Dana Farber Cancer Institute Clinical Trials ProjectManager
mi
from
Boston, MA
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Dana Farber Cancer Institute Clinical Trials ProjectManager
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Nevada Cancer Institute NVCC - Huntsman
mi
from
Las Vegas, NV
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Nevada Cancer Institute NVCC - Huntsman
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Cancer Centers of the Carolinas CCC Faris
mi
from
Greenville, SC
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Cancer Centers of the Carolinas CCC Faris
mi
from
Greenville, SC
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(2)
mi
from
Nashville, TN
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(2)
mi
from
Nashville, TN
Click here to add this to my saved trials